Kingmed Diagnostics(603882) 证券时报网·2024-12-24 09:59Core Insights - The Guangzhou Data Exchange has launched its first medical testing data product for on-site trading, marking a significant step in the compliant trading of medical testing data in China [1][5][12] - The collaboration between KingMed Diagnostics and Shanghai Chenxi Technology Group aims to enhance the precision of medical resources and improve patient treatment through data empowerment [2][6][12] - KingMed Diagnostics has developed a range of data products, including a tuberculosis drug resistance map and a cervical cancer screening big data analysis report, which have passed compliance audits and are now available on the Guangzhou Data Exchange [2][3][11] Company Developments - KingMed Diagnostics has identified six major data resources, including respiratory pathogen targeted sequencing datasets, which have undergone initial property registration audits at the Guangzhou Data Exchange [3][7] - The company is actively collaborating with various organizations in disease monitoring, AI model training, and research projects, contributing to the innovation of the biopharmaceutical industry [4][10] - KingMed Diagnostics has publicly released its first data asset directory, encompassing over 3 billion testing data across various diseases, which supports comprehensive healthcare solutions [11] Industry Trends - The medical health data market in China is evolving towards a new era of "data elements × healthcare," with increasing recognition of the value of healthcare data and a shift towards data productization and standardized circulation [5][13] - The healthcare data market is projected to reach nearly 170 billion yuan by 2028, indicating significant growth potential in the sector [13] - The successful transaction of the first third-party medical testing data product represents a major breakthrough in the compliant circulation of medical testing data in China [12]